To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study. Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms. The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Thanks to recent developments in cryo-electron microscopy, a study led by a team from the I2BC reveals, at the atomic scale, the unsuspected structural complexity of lanreotide nanotubes, a drug used in the treatment of acromegaly and some neuro-endocrine cancers.
A collaboration initiated in 2017 between AP-HP (Bichat Hospital), Paris-Saclay University (Inserm 1193) and the Laboratoire d’Études du Métabolisme des Médicaments (LEMM/SPI/DMTS), leading to 4 publications in 2021, is advancing knowledge on the origin of certain congenital disorders of glycosylation, through the identification of specific biochemical biomarkers.
Researchers from NeuroSpin designed, trained and tested biologically plausible artificial deep neural networks to identify pictures and written words. They show that these may suffice to account for emergence during reading acquisition of the visual word form area, a specific region underlying orthographic coding.
Researchers from the DMTS and I2BC depatments of the Joliot Institute's " identify three potential new biomarkers of senescent cells containing persistent DNA damage.
A collaborative study led by BioMaps researchers (SHFJ) demonstrates that fully integrated quantitative multiparametric analysis of non-small cell lung cancer in hybrid 18F-FDG PET/MRI 3T imaging is clinically feasible and could enable biological characterization of tumors at the supervoxel scale.
Researchers from BioMaps (SHFJ) and the Service de Neurologie de la Mémoire et du Langage (Hôpital Ste-Anne) show, through amyloid and tau molecular imaging in patients followed for 2 years, that the diagnosis of progressive amnesia in the elderly is not necessarily Alzheimer's disease and may be caused by other mechanisms clearly distinguishable from it.
Researchers from the Laboratory of Food Immuno-Allergy (SPI/DMTS), in collaboration with the Necker-Enfants Malades Hospital, identify an immune signature of severe asthma (SA) in children, through a non-targeted global analysis of all immune and inflammatory constituents present in blood and bronchoalveolar lavages of children with SA.
September 2021, the 11.7 Tesla MRI of the Iseult project, the most powerful in the world for human imaging, has just unveiled its first images.
The European Commission once more places its trust on Multiwave company and its partners, Aix-Marseille Université , CEA and Université Catholique de Louvain to revolutionize ultra-high field magnetic resonance imaging of the brain.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.
